The decision was made considering current situation with the spread of coronavirus in the world and will obviously impact marketing authorisation timelines.
This concerns manufacturers of medicines and medical devices from China, South Korea, Iran, Singapore, Malaysia, Italy, Japan, Thailand, USA, Vietnam, Germany, Australia, UAE, the UK and France.
For detailed information refer to the official source: www.ndda.kz
In case of any questions, please, contact us: info@smart-pharma.group